National Heart Centre Singapore will NEVER ask you to transfer money over a call. If in doubt, call the 24/7 ScamShield helpline at 1799, or visit the ScamShield website at www.scamshield.gov.sg.

Dr Koh Si Ya Natalie

MBBS, MMed (Int Med), MRCP (UK)

Senior Consultant

National Heart Centre Singapore National Heart Centre Singapore

Specialty: Cardiology

Clinical Interests

Cardiac Computed Tomography, Cardiometabolic Disease, Echocardiography

Clinical Appointments

Senior Consultant

Cardiology

Senior Consultant

NHCS Cardiology @ SKH

About Doctor

​Dr Natalie Koh is a Senior Consultant from Department of Cardiology at National Heart Centre Singapore and NHCS Cardiology @ Sengkang General Hospital. Her clinical interests are in cardiometabolic disease, preventive cardiology, cardiac computed tomography, CT myocardial perfusion and echocardiography.

She is board-certified in cardiac computed tomography and echocardiography, and helped establish and leads the Cardiac CT Laboratory at Sengkang General Hospital. Her work focuses on integrating cardiovascular and metabolic risk assessment, biomarkers, advanced imaging and evidence-based therapies to identify patients at elevated cardiovascular risk and intervene earlier.

Dr Koh completed an MOH-funded HMDP fellowship at Stanford University in advanced cardiac imaging and cardiometabolic disease. She also holds an MBA, and a Master of Science in Clinical Informatics Management from Stanford University.

Her current work includes developing clinical pathways in cardiometabolic care and precision prevention, and translating advanced imaging techniques into practical workflows across hospitals and disciplines.

She has authored and co-authored peer-reviewed work across advanced cardiac imaging, dyslipidaemia, cardiometabolic risk and preventive cardiology, including first-author publications on Asia-Pacific dyslipidaemia recommendations and the role of cardiac imaging in acute chest pain.

Languages Spoken

  • English

Education and Training

  • ​MBBS (S'pore)
  • MMed (Int Med)
  • MRCP (UK)

Professional Appointments and Committee Memberships

  • Senior Consultant, Department of Cardiology, National Heart Centre Singapore, May 2025 to Present
  • Consultant, Department of Cardiology, National Heart Centre Singapore, May 2020 to Apr 2025
  • ​Associate Consultant, Department of Cardiology, National Heart Centre Singapore, 2018 to April 2020

Publications

  1. Koh N, et al. Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. European Cardiology Review. 2021;16:e54. 
  2. Koh N, Nieman K. Role of cardiac imaging in acute chest pain. British Journal of Radiology. 2023;96(1143):20220307. 
  3. Koh N, et al. Angiotensin receptor–neprilysin inhibitor improves NYHA class and NT-proBNP levels: initial experience in a Singapore single-centre cohort. Singapore Medical Journal. 2021;62(7):359–361. 
  4. Tan JWC, et al. Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. European Cardiology Review. 2021;16:e14.
  5. Li JJ, et al. Tackling cardiometabolic risk in the Asia Pacific region. American Journal of Preventive Cardiology. 2020;4:100096.
  6. Li JJ, et al. Statin intolerance: an updated narrative review mainly focusing on muscle adverse effects. Expert Opinion on Drug Metabolism & Toxicology. 2020;16(9):837–851.
  7. Tada H, et al. Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in the Asia-Pacific Region. JACC: Asia. 2021;1(3):294–302.
  8. Huang Z, et al. Patterns of motivators and barriers to heart health behaviours among adults with behaviour-modifiable cardiovascular risk factors: a population-based survey in Singapore. PLOS ONE. 2022;17(1):e0262752.
  9. Tan JWC, et al. Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Obstructive Sleep Apnoea in Patients with Cardiovascular Disease. European Cardiology Review. 2022;17:e16.
  10. Elshorbagy A, et al. Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study. The Lancet Diabetes & Endocrinology. 2024;12(11):811–823.